Melanoma vaccines: clinical status and immune endpoints
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer /von 2018-09-26 / Cancers (Basel) 2018 Sep;10(10)The Role of Oncolytic Viruses in the Treatment of Melanoma
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-08-25 / Curr Oncol Rep 2018 08;20(10):80Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-08-05 / BMJ Open 2018 08;8(8):e021701Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-26 / Oncoimmunology 2018;7(7):e1445457
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de